Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 10, 2017

Risk of Malignant Mesothelioma Plateaus Four Decades After First Asbestos Exposure, Italian Study Reports

News

The risk of developing or dying from some cancers increases steadily over time. Scientists thought that was the case with malignant pleural mesothelioma, too, but an Italian study shows the ... Read more

August 8, 2017August 8, 2017

Breast, Ovarian Cancer Therapies Induce Malignant Pleural Mesothelioma Cell Death, Study Shows

News

Tesaro (niraparib) and Lymparza (olaparib) — both PARP1 inhibitors approved by the U.S. Food and Drug Administration to treat breast and ovarian cancer patients — also kill malignant pleural mesothelioma (MPM) ... Read more

August 3, 2017

High Platelet Counts Associated with Lower Survival in MPM Surgery Patients

News

Elevated platelet levels in malignant peritoneal mesothelioma (MPM) patients being considered for surgery is associated with poor outcomes, a cohort study shows. The study, “Preoperative Thrombocytosis Predicts Shortened Survival in Patients ... Read more

May 9, 2017May 9, 2017

MicroRNA Levels Could Help Distinguish Malignant Mesothelioma from Lung Cancer, Study Reports

News

Analyzing the levels of microRNA (miRNA)-130a in cells collected from pleural effusions, a condition in which fluid accumulates between the thin membranes surrounding the lungs, may help distinguish malignant pleural ... Read more

April 20, 2017April 20, 2017

Combination of Blood Biomarkers May Speed Diagnosis of Malignant Mesothelioma

News

Detecting a combination of biomarkers already linked to malignant mesothelioma may significantly improve the sensitivity and specificity of screening tests, allowing a more accurate and reliable early diagnosis, new research reports. The study, “A ... Read more

April 17, 2017May 25, 2017

ADI-PEG 20, Chemo Triple Combo Promotes Cancer Cell Death in Some MPM Patients, Study Shows

News

Depleting the amino acid arginine using a drug called ADI-PEG 20 enhances the efficacy of two well-established chemotherapy medications — Platinol (cisplatin) and Alimta (pemetrexed) — in patients with ASS1-deficient ... Read more

April 13, 2017April 13, 2017

Newly Identified Protein Variation May Make Mesothelioma More Vulnerable to Therapy, Study Reports

News

A newly identified form of BRCA1-associated protein-1 (BAP1) increases malignant pleural mesothelioma cells’ vulnerability to some cancer therapies, a study indicates. The findings suggest a new strategy for treating patients ... Read more

August 16, 2016August 16, 2016

First Mesothelioma Patient Treated with Tazemetostat in Global Phase 2 Trial

News

Epizyme announced that researches have initiated treatment of a first patient in the Phase 2 clinical trial of its first-in-class EZH2 inhibitor, tazemetostat, in adults with malignant mesothelioma. EZH2 is an enzyme that induces a type of ... Read more

July 28, 2016July 28, 2016

Two with Mesothelioma Respond to New Therapy Combo Using Lurbinectedin

News

A new mesothelioma treatment based on the marine-derived drug lurbinectedin showed promising results in a preliminary study in two patients who had previously failed to respond to conventional therapy. The study, ... Read more

July 14, 2016July 14, 2016

Specific Inhibitors Can Reduce Mesothelioma Tumor Growth, According to Study

News

Inhibitors of a specific receptor, P2X7, decrease tumor growth in malignant pleural mesothelioma, according to the results of a study titled “P2X7 targeting inhibits growth of human mesothelioma,” published in the journal ... Read more